<?xml version="1.0" encoding="UTF-8"?><BillSummaries>
<item congress="114" measure-type="s" measure-number="1077" measure-id="id114s1077" originChamber="SENATE" orig-publish-date="2015-04-23" update-date="2016-03-09">
<title>Advancing Breakthrough Devices for Patients Act of 2015</title>
<summary summary-id="id114s1077v00" currentChamber="SENATE" update-date="2016-03-09">
<action-date>2015-04-23</action-date>
<action-desc>Introduced in Senate</action-desc>
<summary-text><![CDATA[<p><b>Advancing Breakthrough Devices for Patients Act of 2015</b></p> <p>This bill amends the Federal Food, Drug, and Cosmetic Act to expand the Food and Drug Administration's (FDA's) priority review of breakthrough medical devices to include all classes of devices. Currently, only class III (new or highest risk) devices are eligible.</p> <p>Upon a sponsor's request, the FDA must determine whether a device meets the criteria for priority review as a breakthrough device.</p> <p>To expedite the development and review of designated medical devices, the FDA must:</p> <ul> <li>assign a team of staff for each device, </li> <li>adopt an efficient process for dispute resolution, </li> <li>provide for interactive and timely communication with the device sponsor, </li> <li>expedite review of manufacturing and quality systems compliance, </li> <li>disclose to the sponsor in advance the topics of any consultation between the FDA and external experts or an advisory committee and provide the sponsor the opportunity to recommend external experts, </li> <li>assign staff to address questions by institutional review committees concerning investigational use of the device. </li></ul>The FDA may: (1) coordinate with the sponsor regarding early agreement on a data development plan; (2) take steps to ensure that the design of clinical trials is as efficient as practicable; (3) utilize timely postmarket data collection; and (4) agree to clinical protocols, subject to a decision that a substantial scientific issue essential to determining the safety or effectiveness of the device exists.]]></summary-text>
</summary>
</item>
<dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
<dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
<dc:description>This file contains bill summaries for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
</dublinCore>
</BillSummaries>
